Latest Conference Coverage

Combination of Higher Dose ApTOLL and EVT Reduces Mortality and Disability in Ischemic Stroke

At the conclusion of the trial, treatment with 0.2 mg/kg of ApTOLL with EVT resulted in reduced brain edema and hemorrhagic transformation, as well as fewer deaths than placebo and 0.05 mg groups.

3-Year Follow-Up of STROKE-AF Demonstrates Stroke Risk Increase With Atrial Fibrillation

Patients with noncardioembolic ischemic stroke do not typically monitor post-stroke longterm to detect atrial fibrillation although findings from a trial follow-up suggest otherwise.

NeuroVoices: Shumei Man, MD, on How Collaboration Between Hospitals Reduces Readmission for Stroke

The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.

Future Plans for ALZ-801 in Homo- and Heterozygous Populations: Susan Abushakra, MD

The chief medical officer at Alzheon provided perspective on the next steps for ALZ-801 following a successful phase 2 study of patients with APOE ε4/4 or APOE ε3/4 genotype. [WATCH TIME: 2 minutes]

Intellectual and Electrophysiological Disturbances in the Definition of ‘Seizure’: Michael Sperling, MD

Paroxysmal Abnormalities in the Brain and Defining the ‘Seizure’: Michael Sperling, MD

Weighing Epilepsy Surgery as a Potential Treatment Option for Patients: Scott Perry, MD

Building Trust in the Epilepsy Clinician-Patient Relationship: Elizabeth Felton, MD, PhD

The assistant professor in the Department of Neurology at the University of Wisconsin spoke about healthcare providers establishing trust with their patients and improving health equity. [WATCH TIME: 3 minutes]

Post-Stroke Seizure Predictive Models, SeLECT Model: Carolina Ferreira Atuesta, MD, MSc

The scientific researcher and clinical manager, Icahn School of Medicine at Mount Sinai, spoke about the clinical models used to predict seizures in poststroke patients. [WATCH TIME: 4 minutes]

Influence of Antiepileptic Medications on Seizure Frequency in Insomnia: Milena Pavlova, MD

At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about seizure frequency and insomnia. [WATCH TIME: 2 minutes]

Poststroke Epilepsy Management With Antiseizure Medication: Carolina Ferreira Atuesta, MD, MSc

At the 2022 AES Conference, the scientific researcher and clinical manager at the Icahn School of Medicine at Mount Sinai talked on seizure management with medication in poststroke patients. [WATCH TIME: 3 minutes]

Understanding ALZ-801’s Impact on Alzheimer Pathologies, Brain Atrophy

Susan Abushakra, MD, chief medical officer at Alzheon, provided insight on findings from a phase 2 study in which ALZ-801 showed beneficial effects on cognition, Aß 42/40, and brain atrophy.

Worse Clinical Outcomes, Higher Mortality Rates, and Shorter Lifespans in Epilepsy and Dementia: Ifrah Zawar, MD

The assistant professor of neurology at the University of Virginia spoke at the 2022 AES Conference about clinical outcomes of patients with dementia who experience seizures. [WATCH TIME: 5 minutes]

Poststroke Epilepsy and Cerebrovascular Disease: Carolina Ferreira Atuesta, MD, MSc

The scientific researcher and clinical manager at the Icahn School of Medicine at Mount Sinai, spoke about a talk given at the 2022 AES conference on seizures after ischemic. [WATCH TIME: 5 minutes]

NeuroVoices: RJ Tesi, MD, on XPro1595 and the Role of TNF Inhibitors in the Alzheimer Field

The president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.

Difference Between Health Equity and Health Disparities in Epilepsy: Elizabeth Felton, MD, PhD

The assistant professor in the Department of Neurology at the University of Wisconsin spoke about the differences between health disparities and health equity in epilepsy care at the 2022 AES Conference. [WATCH TIME: 3 minutes]

Debating Surgery in Genetic Disorders with Epilepsy: Scott Perry, MD

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center spoke about his experience in a debate on surgery in genetic disorders at the 2022 AES Conference. [WATCH TIME: 3 minutes]

The Definition of a Seizure, Clinical Controversies: Michael Sperling, MD

The Baldwin Keyes professor of neurology at Thomas Jefferson University, spoke with us at the 2022 AES Conference about the definition of a seizure. [WATCH TIME: 3 minutes]

Results from the Subgroup Analysis of BECOME Caregiver Survey: Robert Iannone, MD, MSCE

The executive vice president of Global Head of Research and Development at Jazz Pharmaceuticals, spoke on the results from the BECOME study presented at the 2022 AES Conference. [WATCH TIME: 6 minutes]

Rare Epilepsies, Comorbidities, and Genetic Therapies: Danielle Andrade, MD, MSc, FRCPC

The professor of neurology at the University of Toronto talked about 3 conditions that were discussed during the epilepsy therapies symposium at the 2022 AES Conference. [WATCH TIME: 5 minutes]

Creating Innovative Ways to Improve Alzheimer Disease Prevention: Miia Kivipelto, MD, PhD

The professor of clinical geriatric epidemiology at Karolinska Institutet discussed strategies for lowering the risk of Alzheimer disease, and the new ways to approach prevention. [WATCH TIME: 4 minutes]

Genetic Approaches to Comorbidities in Epilepsy, Dravet Syndrome: Danielle Andrade, MD, MSc, FRCPC

The professor of neurology at the University of Toronto spoke at the 2022 AES Conference about genetic approaches to comorbidities for patients with epilepsy. [WATCH TIME: 5 minutes]

Preventing Epilepsy Through Antiseizure Medication in Tuberous Sclerosis Complex: Gabrielle Rushing, PhD

The director of research at the TSC Alliance spoke with us at the 2022 AES Conference about future research to be conducted on patients with TSC such as the PREVeNT trial. [WATCH TIME: 6 minutes]

Understanding the Long-Term Role of Brain-Derived Neurotrophic Factor Following Lifestyle Changes: Miia Kivipelto, MD, PhD

The professor of clinical geriatric epidemiology at Karolinska Institutet discussed a subgroup analysis of the FINGERS trial and the clinical utility of the precursor to serum brain-derived neurotrophic factor. [WATCH TIME: 3 minutes]

Need for a Multifactoral Approach to Treat Alzheimer Disease: Nicolas Villain, MD

The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided perspective on the reasons to not solely rely on anti-amyloid treatments to treat Alzheimer disease. [WATCH TIME: 3 minutes]

NeuroVoices: Eric Reiman, MD, on Entering a New Era of Prevention in Alzheimer Disease

Sleep Studies Determine Sleep Disorders in Patients with Epilepsy: Milena Pavlova, MD

At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about sleep testing for patients with epilepsy. [WATCH TIME: 3 minutes]

Interactions Between Sleep Disorders and Epilepsy in Adults: Milena Pavlova, MD

The associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital spoke about sleep disorders and epilepsy in adults at the 2022 AES annual meeting. [WATCH TIME: 5 minutes]

Tempering Expectations on High-Clearance Anti-Amyloid Immunotherapies in Alzheimer Disease: Nicolas Villain, MD

The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided background on a study presented at CTAD 2022 assessing the efficacy of prominent, up-and-coming anti-amyloid therapies. [WATCH TIME: 7 minutes]

NeuroVoices: Miia Kivipelto, MD, PhD, on Using Multidomain Interventions to Prevent Cognitive Decline

The professor of clinical geriatric epidemiology at Karolinska Institutet provided perspective on the FINGERS trial, the first study to show it is possible to prevent cognitive decline using a multidomain lifestyle intervention.